| 1 | Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer | 9.3 | 24 | Citations (PDF) |
| 2 | Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation | 4.2 | 33 | Citations (PDF) |
| 3 | Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non–Small Cell Lung Cancer | 6.8 | 13 | Citations (PDF) |
| 4 | Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer | 25.2 | 172 | Citations (PDF) |
| 5 | The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer | 6.8 | 34 | Citations (PDF) |
| 6 | Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer | 6.8 | 34 | Citations (PDF) |
| 7 | Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study 2023, 11, e006994 | | 10 | Citations (PDF) |
| 8 | First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial | 2.1 | 295 | Citations (PDF) |
| 9 | Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status | 2.1 | 342 | Citations (PDF) |
| 10 | Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab | 2.0 | 19 | Citations (PDF) |
| 11 | First-Line Immunotherapy for Non–Small-Cell Lung Cancer | 16.9 | 799 | Citations (PDF) |
| 12 | A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry | 2.1 | 21 | Citations (PDF) |
| 13 | TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion | 9.3 | 142 | Citations (PDF) |
| 14 | Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer | 1.1 | 29 | Citations (PDF) |
| 15 | Fundamental immune–oncogenicity trade-offs define driver mutation fitness | 37.9 | 75 | Citations (PDF) |
| 16 | Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions | 9.3 | 47 | Citations (PDF) |
| 17 | Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer 2022, 10, e004440 | | 115 | Citations (PDF) |
| 18 | Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels | 14.3 | 322 | Citations (PDF) |
| 19 | Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer | 6.8 | 48 | Citations (PDF) |
| 20 | Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort | 25.1 | 76 | Citations (PDF) |
| 21 | Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy | 6.8 | 118 | Citations (PDF) |
| 22 | Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade | 25.1 | 66 | Citations (PDF) |
| 23 | Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors | 6.8 | 102 | Citations (PDF) |
| 24 | Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer | 6.8 | 117 | Citations (PDF) |
| 25 | Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade 2021, 9, e001884 | | 60 | Citations (PDF) |
| 26 | Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionCell, 2021, 184, 596-614.e14 | 33.6 | 822 | Citations (PDF) |
| 27 | Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child | 33.0 | 105 | Citations (PDF) |
| 28 | Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics | 4.9 | 54 | Citations (PDF) |
| 29 | Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity | 33.0 | 173 | Citations (PDF) |
| 30 | Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer | 6.8 | 76 | Citations (PDF) |
| 31 | Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers | 37.9 | 509 | Citations (PDF) |
| 32 | Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research | 33.0 | 1 | Citations (PDF) |
| 33 | The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors | 2.1 | 16 | Citations (PDF) |
| 34 | Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab | 9.9 | 28 | Citations (PDF) |
| 35 | Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project | 9.9 | 168 | Citations (PDF) |
| 36 | Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer | 2.6 | 5 | Citations (PDF) |
| 37 | Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers | 5.5 | 22 | Citations (PDF) |
| 38 | First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting | 5.1 | 236 | Citations (PDF) |
| 39 | Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort | 2.1 | 267 | Citations (PDF) |
| 40 | Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer | 25.1 | 318 | Citations (PDF) |
| 41 | Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer | 2.0 | 29 | Citations (PDF) |
| 42 | A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerCell, 2020, 183, 347-362.e24 | 33.6 | 673 | Citations (PDF) |
| 43 | Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen PredictionCell, 2020, 183, 818-834.e13 | 33.6 | 508 | Citations (PDF) |
| 44 | Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionCell, 2020, 183, 363-376.e13 | 33.6 | 313 | Citations (PDF) |
| 45 | Escape from nonsense-mediated decay associates with anti-tumor immunogenicity | 13.7 | 97 | Citations (PDF) |
| 46 | The Genomic Landscape of
SMARCA4
Alterations and Associations with Outcomes in Patients with Lung Cancer | 6.8 | 269 | Citations (PDF) |
| 47 | Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade | 25.1 | 314 | Citations (PDF) |
| 48 | Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers | 25.1 | 221 | Citations (PDF) |
| 49 | Protein-altering germline mutations implicate novel genes related to lung cancer development | 13.7 | 44 | Citations (PDF) |
| 50 | Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab | 2.6 | 57 | Citations (PDF) |
| 51 | Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer | 4.3 | 39 | Citations (PDF) |
| 52 | COVID-19 in patients with lung cancer | 9.9 | 234 | Citations (PDF) |
| 53 | Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas | 9.9 | 282 | Citations (PDF) |
| 54 | New Approaches to SCLC Therapy: From the Laboratory to the Clinic | 2.1 | 168 | Citations (PDF) |
| 55 | Clinical outcomes, local–regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab | 2.0 | 54 | Citations (PDF) |
| 56 | Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer | 6.8 | 145 | Citations (PDF) |
| 57 | Acquired Resistance to Immune Checkpoint Inhibitors | 33.0 | 864 | Citations (PDF) |
| 58 | Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project 2020, 8, e000147 | | 459 | Citations (PDF) |
| 59 | Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC | 6.8 | 113 | Citations (PDF) |
| 60 | Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images | 7.8 | 240 | Citations (PDF) |
| 61 | Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
EGFR
-Mutant Lung Cancers | 6.8 | 320 | Citations (PDF) |
| 62 | Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeCell, 2019, 178, 933-948.e14 | 33.6 | 489 | Citations (PDF) |
| 63 | Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes | 2.1 | 393 | Citations (PDF) |
| 64 | Use of Circulating Tumor DNA for Cancer Immunotherapy | 6.8 | 41 | Citations (PDF) |
| 65 | TOX is a critical regulator of tumour-specific T cell differentiation | 37.9 | 1,040 | Citations (PDF) |
| 66 | Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade | 16.9 | 100 | Citations (PDF) |
| 67 | Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC | 2.1 | 90 | Citations (PDF) |
| 68 | Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | 34.5 | 2,579 | Citations (PDF) |
| 69 | Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers | 1.9 | 102 | Citations (PDF) |
| 70 | EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer | 9.9 | 346 | Citations (PDF) |
| 71 | Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | 16.9 | 1,095 | Citations (PDF) |
| 72 | Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer | 6.8 | 73 | Citations (PDF) |
| 73 | Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis | 6.8 | 302 | Citations (PDF) |
| 74 | Rational design of anti-GITR-based combination immunotherapy | 33.0 | 218 | Citations (PDF) |
| 75 | Neoantigen-directed immune escape in lung cancer evolution | 37.9 | 867 | Citations (PDF) |
| 76 | Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib | 9.9 | 368 | Citations (PDF) |
| 77 | Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors | 9.9 | 156 | Citations (PDF) |
| 78 | Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study | 23.3 | 168 | Citations (PDF) |
| 79 | Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors | 6.8 | 244 | Citations (PDF) |
| 80 | Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 | 2.1 | 289 | Citations (PDF) |
| 81 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types | 25.2 | 3,580 | Citations (PDF) |
| 82 | Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics | 6.1 | 48 | Citations (PDF) |
| 83 | Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer | 3.8 | 305 | Citations (PDF) |
| 84 | A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers | 4.6 | 119 | Citations (PDF) |
| 85 | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer | 34.5 | 1,887 | Citations (PDF) |
| 86 | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | 34.5 | 2,875 | Citations (PDF) |
| 87 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer | 33.0 | 1,002 | Citations (PDF) |
| 88 | PD-1/PD-L1 Axis in Lung Cancer | 1.8 | 76 | Citations (PDF) |
| 89 | KEYNOTE-024: Unlocking a pathway to lung cancer cure? | 2.6 | 10 | Citations (PDF) |
| 90 | Immune-Related Adverse Events Associated with Immune Checkpoint Blockade | 34.5 | 4,439 | Citations (PDF) |
| 91 | Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer | 33.0 | 828 | Citations (PDF) |
| 92 | Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance | 6.8 | 244 | Citations (PDF) |
| 93 | Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
KRAS
-Mutant Non–Small Cell Lung Cancer | 6.8 | 446 | Citations (PDF) |
| 94 | Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders | 16.9 | 318 | Citations (PDF) |
| 95 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer | 16.9 | 973 | Citations (PDF) |
| 96 | Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing | 16.9 | 1,314 | Citations (PDF) |
| 97 | Acquired resistance to immunotherapy in MMR-D pancreatic cancer 2018, 6, | | 33 | Citations (PDF) |
| 98 | Lung Cancer with a High Tumor Mutational Burden | 34.5 | 20 | Citations (PDF) |
| 99 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma | 25.1 | 1,535 | Citations (PDF) |
| 100 | Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition | 1.3 | 41 | Citations (PDF) |
| 101 | 30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT) | 5.3 | 10 | Citations (PDF) |
| 102 | Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC | 2.1 | 164 | Citations (PDF) |
| 103 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) 2018, 6, | | 237 | Citations (PDF) |
| 104 | Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC | 4.2 | 321 | Citations (PDF) |
| 105 | Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity | 33.0 | 138 | Citations (PDF) |
| 106 | Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC | 4.2 | 533 | Citations (PDF) |
| 107 | Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients | 33.0 | 3,143 | Citations (PDF) |
| 108 | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study | 27.4 | 945 | Citations (PDF) |
| 109 | Chromatin states define tumour-specific T cell dysfunction and reprogramming | 37.9 | 890 | Citations (PDF) |
| 110 | Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies | 25.1 | 602 | Citations (PDF) |
| 111 | Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas | 2.6 | 60 | Citations (PDF) |
| 112 | Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab | 4.6 | 68 | Citations (PDF) |
| 113 | Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade | 4.2 | 178 | Citations (PDF) |
| 114 | Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors | 2.3 | 91 | Citations (PDF) |
| 115 | Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy | 13.7 | 170 | Citations (PDF) |
| 116 | Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung CancerCell, 2017, 171, 1284-1300.e21 | 33.6 | 489 | Citations (PDF) |
| 117 | A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy | 37.9 | 653 | Citations (PDF) |
| 118 | Identification and Functional Characterization of
EGFR
V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas | 1.9 | 12 | Citations (PDF) |
| 119 | Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis | 8.0 | 326 | Citations (PDF) |
| 120 | OncoKB: A Precision Oncology Knowledge Base | 1.9 | 1,958 | Citations (PDF) |
| 121 | Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors | 2.3 | 67 | Citations (PDF) |
| 122 | Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas | 2.1 | 4 | Citations (PDF) |
| 123 | Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Non–Small Cell Lung Cancers: The NEOSCAN Trial | 2.1 | 45 | Citations (PDF) |
| 124 | Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets | 6.8 | 441 | Citations (PDF) |
| 125 | Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas | 2.1 | 106 | Citations (PDF) |
| 126 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer | 34.5 | 5,972 | Citations (PDF) |
| 127 | Differences in the survival of patients with recurrent versus de novo metastatic KRAS‐mutant and EGFR‐mutant lung adenocarcinomas | 4.0 | 15 | Citations (PDF) |
| 128 | Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancers | 2.8 | 12 | Citations (PDF) |
| 129 | Chemotherapy for Lung Cancers: Here to Stay | 4.4 | 11 | Citations (PDF) |
| 130 | Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers | 2.1 | 121 | Citations (PDF) |
| 131 | Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint | 27.4 | 606 | Citations (PDF) |
| 132 | Opportunistic infections in patients treated with immunotherapy for cancer 2014, 2, 19 | | 110 | Citations (PDF) |
| 133 | Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease | 1.4 | 85 | Citations (PDF) |
| 134 | Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib | 2.1 | 23 | Citations (PDF) |
| 135 | Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab | 2.1 | 14 | Citations (PDF) |
| 136 | High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOPBlood, 2011, 118, 1601-1601 | 4.8 | 1 | Citations (PDF) |
| 137 | The Estimated Magnitude and Direct Hospital Costs of Prosthetic Joint Infections in the United States, 1997 to 2004 | 3.0 | 39 | Citations (PDF) |
| 138 | Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma | 4.0 | 223 | Citations (PDF) |
